Timiperone | 57648-21-2 | antipsychotic

MedKoo Cat#: 581331 | Name: Timiperone

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Timiperone is butyrophenone derivative which has neuroleptic activity. Used as an antipsychotic. Timiperone treatment of mice increased both the porphyrin content of the Harderian gland and the serum prolactin levels.

Chemical Structure

Timiperone

CAS#57648-21-2

Theoretical Analysis

MedKoo Cat#: 581331

Name: Timiperone

CAS#: 57648-21-2

Chemical Formula: C22H24FN3OS

Exact Mass: 397.1624

Molecular Weight: 397.51

Elemental Analysis: C, 66.47; H, 6.09; F, 4.78; N, 10.57; O, 4.02; S, 8.07

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Timiperone; Timiperonum; Tolopelon; Timiperona;

IUPAC/Chemical Name

1-(1-(3-(p-Fluorobenzoyl)propyl)-4-piperidyl)-2-benzimidazolinethione

InChi Key

YDLQKLWVKKFPII-UHFFFAOYSA-N

InChi Code

InChI=1S/C22H24FN3OS/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-10,18H,3,6,11-15H2,(H,24,28)

SMILES Code

S=C1NC2=CC=CC=C2N1C3CCN(CCCC(C4=CC=C(F)C=C4)=O)CC3

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 397.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Boušová I, Skálová L, Souček P, Matoušková P. The modulation of carbonyl reductase 1 by polyphenols. Drug Metab Rev. 2015;47(4):520-33. doi: 10.3109/03602532.2015.1089885. Epub 2015 Sep 29. Review. PubMed PMID: 26415702. 2: Oka T, Hamamura T, Lee Y, Miyata S, Habara T, Endo S, Taoka H, Kuroda S. Atypical properties of several classes of antipsychotic drugs on the basis of differential induction of Fos-like immunoreactivity in the rat brain. Life Sci. 2004 Nov 26;76(2):225-37. PubMed PMID: 15519367. 3: Kajimura T, Satoh H, Watanabe G, Taya K. Effect of hyperprolactinemia induced by pituitary grafts or castration on porphyrin content of the mouse Harderian gland. J Toxicol Sci. 2001 Aug;26(3):151-61. PubMed PMID: 11552298. 4: Shimoda K, Someya T, Morita S, Hirokane G, Yokono A, Shibasaki M, Takahashi S. Plasma concentrations of timiperone and its reduced metabolite in the patients on timiperone. Psychiatry Clin Neurosci. 1998 Oct;52(5):535-40. PubMed PMID: 10215017. 5: Shimoda K, Shibasaki M, Inaba T, Cheung SW, Someya T, Takahashi S. Carbonyl reduction of timiperone in human liver cytosol. Pharmacol Toxicol. 1998 Oct;83(4):164-8. PubMed PMID: 9820877. 6: Abe S, Suzuki T, Hori T, Baba A, Shiraishi H. Hypogammaglobulinemia during antipsychotic therapy. Psychiatry Clin Neurosci. 1998 Feb;52(1):115-7. PubMed PMID: 9682944. 7: Kajimura T, Satoh H, Nomura M. Effect of hyperprolactinemia induced by neuroleptic agent, timiperone, on porphyrin content of mouse harderian gland. J Toxicol Sci. 1997 Aug;22(3):219-29. PubMed PMID: 9279824. 8: Takayasu T, Kakubari I, Fukamachi A, Mafune E, Takasugi N, Takayama K, Nagai T. Determination of timiperone in rat plasma by high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl. 1996 Apr 26;679(1-2):161-5. PubMed PMID: 8998556. 9: Tsujii T, Yonese J, Tari K. [Antiemetic efficacy of intravenous timiperone in emesis induced by a 5-day-course of cisplatin]. Gan To Kagaku Ryoho. 1989 Sep;16(9):3307-9. Japanese. PubMed PMID: 2571324. 10: Nishikawa T, Tanaka M, Tsuda A, Koga I, Uchida Y. Prophylactic effects of neuroleptics in symptom-free schizophrenics: a comparative dose-response study of timiperone and sulpiride. Biol Psychiatry. 1989 Apr 1;25(7):861-6. PubMed PMID: 2655717. 11: Tsujii T, Tari K, Yonese J, Kojima S. [Antiemetic effect of timiperone and methylprednisolone in cisplatin-induced emesis]. Gan To Kagaku Ryoho. 1988 Jul;15(7):2101-5. Japanese. PubMed PMID: 3395137. 12: Tari K, Satake I, Kojima S, Owada F. [Antiemetic therapy with timiperone in cisplatin-induced vomiting]. Gan To Kagaku Ryoho. 1986 Sep;13(9):2848-52. Japanese. PubMed PMID: 3753027. 13: Tanaka M, Kojima H, Akashi A. Effect of timiperone, a new antipsychotic drug, on the sleep-wakefulness cycle in cats. Jpn J Pharmacol. 1985 Nov;39(3):391-4. PubMed PMID: 2869168. 14: Tari K, Satake I, Takahashi M, Matsuzawa M, Akazawa S. [Prophylactic efficacy of timiperone (Tolopelon) in vomiting caused by DDP]. Gan To Kagaku Ryoho. 1985 Jan;12(1):166-8. Japanese. PubMed PMID: 4038448. 15: Tanaka M, Kojima H, Akashi A. [An electroencephalographical study on timiperone, a new antipsychotic drug]. Nihon Yakurigaku Zasshi. 1984 Aug;84(2):213-9. Japanese. PubMed PMID: 6489867. 16: Sudo K, Tachizawa H. Protein binding of timiperone, 4'-fluoro-4-[4-(2-thioxo-1-benzimidazolinyl)piperidino]butyrophenone, a neuroleptic. Chem Pharm Bull (Tokyo). 1983 Apr;31(4):1411-4. PubMed PMID: 6138166. 17: Sudo K, Tachizawa H. [Autoradiographic studies on the distribution of 14C-labeled timiperone, a new butyrophenone antipsychotic, in the rat and monkey]. Yakugaku Zasshi. 1983 Mar;103(3):342-9. Japanese. PubMed PMID: 6137551. 18: Nakazawa T, Ohara K, Sawa Y, Edakubo T, Matsui H, Sawa J, Kawaguchi K, Hattori S, Nakajima M. Comparison of efficacy of timiperone, a new butyrophenone derivative, and clocapramine in schizophrenia: a multiclinic double-blind study. J Int Med Res. 1983;11(5):247-58. PubMed PMID: 6139317. 19: Kariya T, Shimazono Y, Itoh H, Mori A, Murasaki M, Sugano K, Toru M, Yamashita I. A comparison of the clinical effects of timiperone, a new butyrophenone derivative, and haloperidol on schizophrenia using a double-blind technique. J Int Med Res. 1983;11(2):66-77. PubMed PMID: 6133803. 20: Shibuya T, Nishimori T, Matsuda H, Chen PC. Behavioral pharmacologic studies in the monkey with DD-3480. Int J Clin Pharmacol Ther Toxicol. 1982 Jun;20(6):251-4. PubMed PMID: 6125481.